JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Innoviva Inc

Отворен

СекторЗдравеопазване

17.63 -1.18

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.38

Максимум

17.86

Ключови измерители

By Trading Economics

Приходи

110M

64M

Продажби

12M

100M

P/E

Средно за сектора

30.193

37.461

Марж на печалбата

63.508

Служители

127

EBITDA

111M

84M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+114.81% upside

Дивиденти

By Dow Jones

Следващи печалби

4.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-82M

1.1B

Предишно отваряне

18.81

Предишно затваряне

17.63

Настроения в новините

By Acuity

34%

66%

97 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

Innoviva Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.10.2025 г., 23:50 ч. UTC

Горещи акции

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28.10.2025 г., 23:25 ч. UTC

Печалби

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28.10.2025 г., 23:18 ч. UTC

Печалби

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28.10.2025 г., 22:20 ч. UTC

Печалби

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28.10.2025 г., 22:13 ч. UTC

Печалби

Wal-Mart de Mexico Net Profit Falls in 3Q

28.10.2025 г., 21:38 ч. UTC

Печалби

Correction to Visa Sales Jump Article

28.10.2025 г., 21:17 ч. UTC

Печалби

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28.10.2025 г., 21:07 ч. UTC

Печалби

Visa Sales Jump as Consumers Keep Spending -- Update

28.10.2025 г., 21:02 ч. UTC

Печалби

Mondelez Tempers Outlook as Costs Rise

28.10.2025 г., 23:51 ч. UTC

Пазарно говорене

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28.10.2025 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28.10.2025 г., 23:02 ч. UTC

Печалби

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28.10.2025 г., 23:01 ч. UTC

Печалби

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28.10.2025 г., 22:46 ч. UTC

Печалби

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28.10.2025 г., 22:45 ч. UTC

Печалби

SK Hynix 3Q Net KRW12.6T >000660.SE

28.10.2025 г., 22:44 ч. UTC

Печалби

SK Hynix 3Q Rev KRW24.44T >000660.SE

28.10.2025 г., 22:43 ч. UTC

Печалби

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28.10.2025 г., 22:42 ч. UTC

Печалби

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28.10.2025 г., 22:40 ч. UTC

Печалби

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28.10.2025 г., 22:40 ч. UTC

Печалби

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28.10.2025 г., 22:20 ч. UTC

Печалби

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28.10.2025 г., 22:02 ч. UTC

Печалби

Review & Preview: Earnings Extravaganza -- Barrons.com

28.10.2025 г., 21:42 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

28.10.2025 г., 21:42 ч. UTC

Пазарно говорене
Печалби

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28.10.2025 г., 21:20 ч. UTC

Печалби

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28.10.2025 г., 21:19 ч. UTC

Печалби

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28.10.2025 г., 21:18 ч. UTC

Печалби

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Сравнение с други в отрасъла

Ценова промяна

Innoviva Inc Прогноза

Ценова цел

By TipRanks

114.81% нагоре

12-месечна прогноза

Среден 38 USD  114.81%

Висок 55 USD

Нисък 17 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Innoviva Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

4 ratings

3

Купи

0

Задържане

1

Продай

Техническа оценка

By Trading Central

18.57 / 18.75Подкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

97 / 373 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat